Source content
FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 782
Guide Official Revision Description Reason for Update
Version Date Number Of Change
2026 04/29/2026 12 Medical Policy In Item 48. General
Systemic, the Human
Immunodeficiency Virus
(HIV) disposition table was
updated to include
Yeztugo (lenacapavir) for
PrEP.
2026 04/29/2026 13 Medical Policy In Pharmaceuticals, added
new Osteoporosis
Medications page.
2026 04/29/2026 14 Medical Policy In Pharmaceuticals, added
new Smoking Cessation
Medications page
2026 04/29/2026 15 Medical Policy On Biologics, Biosimilars,
and Non-biologics page,
revised to clarify mechanism.
Changed to conditional,
removed SI as required.
2026 04/29/2026 16 Admin In Pharmaceuticals, added
new Osteoporosis
Medications and Smoking
Cessation Medications and
general information (from
current web page) to
Pharmaceuticals Page
2026 04/29/2026 17 Medical Policy In Item 41. G. U., updated
Low Testosterone (Low T)
Hypogonadism Disposition
Table. Added link to Status
Summary and added
Tamoxifen to row B.
2026 04/29/2026 18 Medical Policy In Item 41. G.U., revised
CACI - Low Testosterone
(Low T) hypogonadism to
allow Tamoxifen. Added link
to status summary.
2026 04/29/2026 19 Medical Policy In Item 41. G.U., revised Low
Testosterone (Low T)
hypogonadism Status
Summary to allow
Tamoxifen.
2026 04/29/2026 20 Medical Policy In Item 38. Abdomen and
Viscera Metabolic
dysfunction-Associated Liver
Disease (MASLD)/Non-
Alcoholic Fatty Liver Disease
Shown as extracted from the FAA PDF, without paraphrasing. Tables and forms may lose their layout. Underlined references open the Guide location they name.
